HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European Commission Evaluating CBD Court Ruling Ahead Of Crucial UN Vote

Executive Summary

With the European Commission "carefully assessing" the judgment of Europe's highest court that CBD is not a narcotic, HBW Insight speaks to an expert in cannabis law about what is likely to happen next.

You may also be interested in...



European Commission Decides CBD Is Not A Drug Opening Up Novel Food Pathway

The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.

UK CBD Pathway Clear As EU Decides

The European Commission thinks that CBD might be a narcotic, after all. What should companies be doing while it decides? In this exclusive interview, regulatory expert Greer Deal – director at Global Regulatory Services – suggests that companies that haven’t already done so should consider filing Novel Food (NF) applications with both the European Commission and the UK Food Standards Agency.

UN Vote On Cannabis Controls Could Be Crucial To CBD’s Future In EU

Legal experts say the EU already prohibits cosmetic use of CBD sourced from hemp flowers, and it now appears that food supplement use could be held to the same standard. The World Health Organization has recommended changes to the half-century-old international treaty governing narcotic controls, which could help to resolve the situation, but there are reports of UN pushback.

Related Content

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel